RE
Posted:
June 10, 2026
Location:
Spain, Spain, Spain
Job Description
Senior Editor - The Lancet’s eBioMedicine
Full time fixed term contract target end date: 31/05/2027
Location: Spain
Would you like to join the Lancet’s family of world-renowned medical research journals?
Do you enjoy driving change with science?
About our Team
eBioMedicine is The Lancet’s translational medicine journal and a leading open-access forum for basic and clinical biomedical research.
We are a collaborative, international team, handling high-quality research, review, and perspective submissions with a focus on rigorous peer review, ethics, and reproducibility. We seek to drive thought leadership in translational research by building solid relationships with research communities and ensuring we offer exciting, thought-provoking content.
At eBioMedicine, we are deeply committed to fostering a diverse, equitable, and inclusive environment. In our pursuit of excellence, we recog...
Full time fixed term contract target end date: 31/05/2027
Location: Spain
Would you like to join the Lancet’s family of world-renowned medical research journals?
Do you enjoy driving change with science?
About our Team
eBioMedicine is The Lancet’s translational medicine journal and a leading open-access forum for basic and clinical biomedical research.
We are a collaborative, international team, handling high-quality research, review, and perspective submissions with a focus on rigorous peer review, ethics, and reproducibility. We seek to drive thought leadership in translational research by building solid relationships with research communities and ensuring we offer exciting, thought-provoking content.
At eBioMedicine, we are deeply committed to fostering a diverse, equitable, and inclusive environment. In our pursuit of excellence, we recog...
Apply for this Job
Submit your application for the Senior Editor - The Lancet’s eBioMedicine position at RELX INC.
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Spain, Spain
Posted:
June 10, 2026
Deadline:
June 15, 2026